Mar 3, 2020 | Uncategorised
Ancaster, ON, March 2, 2020 — TTR Amyloidosis Canada is joined by the Regroupement québécois des maladies orphelines (RQMO) in commending the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence...
Feb 27, 2020 | Uncategorised
TTR Amyloidosis Canada and Regroupement québécois des maladies orphelines (RQMO) are pleased to announce a Call for Proposals for Unfolding Transthyretin Amyloidosis: The Akcea Canada Young Investigator Grants Program. This new research program will...
Dec 19, 2019 | Uncategorised
-First Canadian Program to Stimulate Research into Transthyretin Amyloidosis – Toronto, ON and Montreal, QC , December 19, 2019 — TTR Amyloidosis Canada and Regroupement québécois des maladies orphelines (RQMO) announced today that...
Dec 2, 2019 | Uncategorised
The 2nd European Meeting for ATTR Amyloidosis for Doctors and Patients took place in Berlin, Germany. In attendance were 300 participants, including over 200 doctors from 21 countries across the globe. Patients and caregivers came from Japan, South Korea, Venezuela,...
Dec 2, 2019 | Uncategorised
From October 25-27, 2019, I was able to attend this meeting in Chicago, arranged by Amyloidosis Support Groups. The goal of the conference was to inform and share information about amyloidosis, current and future treatments, clinical trials and research updates....
Nov 22, 2019 | Uncategorised
Thank you to all who were able to join us on November 16 for the Unfolding hATTR: Cardiac Amyloidosis presentation with Dr. Diego Delgado. In case you missed it, you can listen to a recording of the webinar here: If you have any future webinar topic...
Nov 7, 2019 | Uncategorised
Unfolding hATTR: Update on Cardiac Amyloidosis Are you or a loved one living with hereditary ATTR (hATTR) amyloidosis? On behalf of Hereditary Amyloidosis Canada, we’d like to invite you to our first webinar for Canadian patients, caregivers and family members to help...
Jul 24, 2019 | Uncategorised
Alnylam Pharmaceuticals, Inc. Announce Health Canada’s Approval of Onpattro™ (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. To learn more, please...
